Evaluation of a cyclophilin inhibitor in hepatitis C virus-infected chimeric mice in vivo. - Wikidata - wikimedia - TriplyDB

Evaluation of a cyclophilin inhibitor in hepatitis C virus-infected chimeric mice in vivo.

Evaluation of a cyclophilin inhibitor in hepatitis C virus-infected chimeric mice in vivo.

http://www.wikidata.org/entity/Q43036832

about

Human VAP-C negatively regulates hepatitis C virus propagation Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors Cyclophilin Inhibitors Remodel the Endoplasmic Reticulum of HCV-Infected Cells in a Unique Pattern Rendering Cells Impervious to a Reinfection Cyclophilin A Is an Essential Cofactor for Hepatitis C Virus Infection and the Principal Mediator of Cyclosporine Resistance In Vitro Critical Role of Cyclophilin A and Its Prolyl-Peptidyl Isomerase Activity in the Structure and Function of the Hepatitis C Virus Replication Complex Modeling Subgenomic Hepatitis C Virus RNA Kinetics during Treatment with Alpha Interferon Combined antiviral activity of interferon-α and RNA interference directed against hepatitis C without affecting vector delivery and gene silencing Mutations in the hepatitis C virus polymerase that increase RNA binding can confer resistance to cyclosporine A Pathogenesis of Hepatitis C Virus Infection in Tupaia belangeri Chemical derivatives of a small molecule deubiquitinase inhibitor have antiviral activity against several RNA viruses Tupaia belangeri as an experimental animal model for viral infection Challenge pools of hepatitis C virus genotypes 1-6 prototype strains: replication fitness and pathogenicity in chimpanzees and human liver-chimeric mouse models.Profile of alisporivir and its potential in the treatment of hepatitis C.Self-enhancement of hepatitis C virus replication by promotion of specific sphingolipid biosynthesis.Hepatitis C virus virology and new treatment targets.Experimental models for hepatitis C viral infection.New developments in small molecular compounds for anti-hepatitis C virus (HCV) therapy.Cyclophilin inhibitors in hepatitis C viral infection.Hepatitis C Viral Kinetics in Special Populations Hepatitis C virus kinetics by administration of pegylated interferon-α in human and chimeric mice carrying human hepatocytes with variants of the IL28B gene.Avoiding therapeutic pitfalls: the rational use of specifically targeted agents against hepatitis C infection.Imino sugar glucosidase inhibitors as broadly active anti-filovirus agents Know your enemy: translating insights about the molecular biology of hepatitis C virus into novel therapeutic approaches.In vivo therapeutic potential of Dicer-hunting siRNAs targeting infectious hepatitis C virus.HCV animal models: a journey of more than 30 years.Cyclophilin inhibitors as a novel HCV therapy.Synthetic lipophilic antioxidant BO-653 suppresses HCV replication.The Application of Humanized Mouse Models for the Study of Human Exclusive Viruses.Preclinical characterization of naturally occurring polyketide cyclophilin inhibitors from the sanglifehrin family.Mechanism of resistance of hepatitis C virus replicons to structurally distinct cyclophilin inhibitors.An orally available, small-molecule interferon inhibits viral replication.Inhibition of endoplasmic reticulum-resident glucosidases impairs severe acute respiratory syndrome coronavirus and human coronavirus NL63 spike protein-mediated entry by altering the glycan processing of angiotensin I-converting enzyme 2.The cyclophilin inhibitor Debio 025 normalizes mitochondrial function, muscle apoptosis and ultrastructural defects in Col6a1-/- myopathic mice.Update on alisporivir in treatment of viral hepatitis C.Cyclosporine A inhibits hepatitis C virus nonstructural protein 2 through cyclophilin A.Impact of calcineurin inhibitors with or without interferon on hepatitis C virus titers in a chimeric mouse model of hepatitis C virus infection.Of mice and men, calcineurin inhibitors and hepatitis C.The cyclophilin inhibitor Debio-025 shows potent anti-hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus.Use of cyclosporin in a patient with hepatitis C and pustular psoriasis.Genomic polymorphisms in 3β-hydroxysterol Δ24-reductase promoter sequences.

P2860

Q24337683-ED4EBD83-7F9D-4541-AC0D-8886F2788502 Q24645702-8C1B13C8-A2D7-42BF-AA07-9DAB3957D5A9 Q27468931-49ECBFE0-C025-4F78-8C9A-AC6FC1391894 Q27486118-E12849A4-0465-40C9-974D-FE9756E40AAC Q27488788-2EA5B9E3-EC6C-4E4A-A9AC-C7BDAF3F6407 Q27488804-07545B55-DD16-4235-91CA-8875100D0F88 Q27488834-50ECDC3F-085D-48A1-997A-BBF49008A5A6 Q27489369-A2A37DE7-9F4D-4208-9E36-521D19594E23 Q27490544-C206C4C6-0B20-46E0-A060-BC3DDCB8D29E Q28537731-5DFE6730-67E5-4B20-A2C7-FD18F97DCCE2 Q28651439-87794DBE-2298-4C97-B027-0B8F5D698BD4 Q34140014-D091F26E-2C0A-48F9-A3B1-0F205F1D3124 Q34329744-E8B7E611-573B-4600-A7CE-3CBB5DEA24F4 Q34390521-CDFCD139-90B7-4D5E-8BFB-D402A04E2A9A Q34974042-B6DC5AF1-E197-4CDB-8BC6-3690FF2BF530 Q34996679-68D43101-DE8D-4E6F-8D0D-77930753620D Q35653358-81FA2DAE-E0E6-4C5B-B338-7771DC7CB440 Q36916858-E0259B26-CDEA-4508-83EA-FB2CC011F5DE Q37060801-CA73100C-6FFB-475F-94C6-9AA840B35614 Q37130266-B32A1615-6C6C-4B72-AF54-BF7583DF8541 Q37313166-2BC8DE1E-4341-436A-9FAA-ED728010BB99 Q37584342-5CC8C0DC-F26C-4822-B55E-1140B7D53376 Q37688134-0301E4D6-541A-47FE-B711-18B08CF00B18 Q37718105-4C0EAE9F-79D2-43A2-A787-62E8A0A099BD Q37945172-64837FCA-BEBF-4B99-9174-135BDB7092B0 Q38615621-94BB611E-4EFA-4718-ABE1-0D1CC518E35B Q39236220-FB7983BD-F4B6-4D9F-BDEF-8807635DC2EC Q39545359-06E49885-B9CA-47BF-9754-9D55CD47E1A5 Q39579921-44FECAD3-91E5-4CBA-9429-576BC42D1533 Q39736462-78A4B0C1-FF7C-4F29-AE31-5D5560DB599D Q41014830-801CEF87-A8F2-43FA-85A6-CA7BC0F8E1B3 Q41687420-3384315E-6754-48BD-A65B-69078B43F4B9 Q42545449-04F9067D-AAE8-490F-BF60-32F96E3FE248 Q42977561-10D47500-EB95-45C9-87AE-45FCF0A0BB6C Q42991707-1F2104FA-E430-44D8-8DB5-CF3A3AECB05E Q43039673-8474172A-F2EC-41B6-83A8-F736A01827FD Q43041850-92C8F1AA-536B-4D73-9251-5BD730BB15AC Q43046668-87B90CB7-1FA6-4422-B05A-EAAB1AD55616 Q43546286-033B3ADC-C0C0-41CC-A252-C547211B6CCB Q43805723-FE484CC4-FC67-4DB2-BF60-E3E7DAAFC7B9

P2860

Evaluation of a cyclophilin inhibitor in hepatitis C virus-infected chimeric mice in vivo.

http://www.wikidata.org/entity/Q43036832

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年学术文章

@wuu

2007年学术文章

@zh

2007年学术文章

@zh-cn

2007年学术文章

@zh-hans

2007年学术文章

@zh-my

2007年学术文章

@zh-sg

2007年學術文章

@yue

2007年學術文章

@zh-hant

name

Evaluation of a cyclophilin in ...... nfected chimeric mice in vivo.

@en

Evaluation of a cyclophilin in ...... nfected chimeric mice in vivo.

@nl

type

label

Evaluation of a cyclophilin in ...... nfected chimeric mice in vivo.

@en

Evaluation of a cyclophilin in ...... nfected chimeric mice in vivo.

@nl

prefLabel

Evaluation of a cyclophilin in ...... nfected chimeric mice in vivo.

@en

Evaluation of a cyclophilin in ...... nfected chimeric mice in vivo.

@nl

P1433

Q43036832-98F73683-672C-43A7-8672-D43F11B2A288

P1476

Q43036832-761D6F2D-46B4-4368-AF45-CC6BA0B7B763

P2093

Q43036832-134901BA-D421-4FDD-A949-7BA599E11FCF

Q43036832-345DD623-9F7E-496C-BEF9-3231DF724C37

Q43036832-493146CD-EBCC-47B6-A508-49A19412674E

Q43036832-6EAC91BD-B070-4E1B-8DDA-BDCC8EAC4077

Q43036832-7CD29723-332B-4C6F-A251-1F576B2C7125

Q43036832-820A2A33-ED12-46ED-9AF9-7B20889A96D9

Q43036832-8BD4978F-786B-466E-A09E-A0ADA7833B47

Q43036832-A9475F76-B742-4343-80C1-28A40D98F6B8

Q43036832-B05A839F-B29F-4F44-934F-E4D9CE5D2E22

Q43036832-D5BD3E28-1880-40DD-8A72-73CBB53B4183

P2860

Q43036832-7A55B0C9-5B91-42A4-AE00-8CE936E17390

Q43036832-E6B8F3B3-41CA-4D09-8D49-5F183A89BC4C

P304

Q43036832-13A9CB1E-D888-4140-B7BC-A813162CD7D1

P31

Q43036832-158ADC8C-2363-40C1-9F84-9F7751A60D97

P356

Q43036832-9FC4029E-3C5E-410B-8F34-831F8235B3C8

P407

Q43036832-19AA70B3-1AF1-41E9-AEE0-C650A2FDE71C

P433

Q43036832-0DE135B1-DE0A-4263-9859-58BD01E291F7

P478

Q43036832-F4458366-F79D-4957-B790-347C02B8F1E9

P577

Q43036832-3B728088-3612-4D09-8BFE-08086EC2B998

P5875

Q43036832-223EEDB6-27E6-4518-85C6-3B27221F90A8

P698

Q43036832-88AC9D06-6BDE-458B-B9F2-E6AFA352EAB2

P356

P1433

P1476

Evaluation of a cyclophilin in ...... nfected chimeric mice in vivo.

@en

P2093

Fumihiko Yasui

http://www.w3.org/2001/XMLSchema#string

Hiroshi Yasuda

http://www.w3.org/2001/XMLSchema#string

Jean-Maurice Dumont

http://www.w3.org/2001/XMLSchema#string

Kazuaki Inoue

http://www.w3.org/2001/XMLSchema#string

Makoto Yoshiba

http://www.w3.org/2001/XMLSchema#string

Michinori Kohara

http://www.w3.org/2001/XMLSchema#string

Pietro Scalfaro

http://www.w3.org/2001/XMLSchema#string

Takuya Umehara

http://www.w3.org/2001/XMLSchema#string

Tsunamasa Watanabe

http://www.w3.org/2001/XMLSchema#string

Urs T Ruegg

http://www.w3.org/2001/XMLSchema#string

P2860

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

Near completely humanized liver in mice shows human-type metabolic responses to drugs.

P304

921-928

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/HEP.21587

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

45

http://www.w3.org/2001/XMLSchema#string

P577

2007-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51376963

http://www.w3.org/2001/XMLSchema#string

P698

17393519

http://www.w3.org/2001/XMLSchema#string